Best Oral Antiviral for Daily Suppressive HSV Genital Therapy
For daily suppressive therapy of genital herpes, valacyclovir or famciclovir are preferred over acyclovir due to superior dosing convenience (twice daily vs. twice daily for acyclovir), which improves adherence for long-term suppression. Among these, valacyclovir offers the additional advantage of once-daily dosing options and is the only antiviral FDA-approved for once-daily suppressive therapy 1.
Recommended Suppressive Regimens
The CDC guidelines provide multiple acceptable options 1:
First-line choices:
- Valacyclovir 500 mg once daily (most convenient)
- Valacyclovir 1000 mg once daily
- Famciclovir 250 mg twice daily
- Acyclovir 400 mg twice daily
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes per year) 1. For these patients, use higher-dose valacyclovir (1000 mg daily) or twice-daily regimens.
Why Valacyclovir or Famciclovir Over Acyclovir?
While all three drugs are comparable in clinical efficacy 1, valacyclovir and famciclovir provide increased ease of administration, which is critical for prolonged treatment 1. The guidelines explicitly note this advantage matters for long-term adherence.
However, head-to-head comparative data shows some nuance:
- One study found valacyclovir superior to famciclovir for viral suppression (HSV detected on 1.3% vs 3.2% of days, relative risk 2.33) 2
- Another trial showed increased risk of recurrence with valacyclovir vs acyclovir (RR 1.16) 3
- A network meta-analysis could not definitively determine superiority among the three drugs 3
Long-term Safety Considerations
Acyclovir has the longest documented safety record (up to 6 years of continuous use), while valacyclovir and famciclovir were documented for only 1 year at the time of the 1998 guidelines 1. The guidelines specifically noted "insufficient experience with famciclovir and valacyclovir prevents recommendation of these drugs for greater than 1 year" 1.
However, this limitation is now outdated - subsequent experience has demonstrated long-term safety of all three agents, and more recent evidence supports their use beyond 1 year 4, 5, 6.
Clinical Algorithm for Selection
Choose valacyclovir 500 mg once daily IF:
- Patient has <10 recurrences per year
- Adherence is a concern
- Patient prefers simplest regimen
Choose valacyclovir 1000 mg once daily OR famciclovir 250 mg twice daily IF:
- Patient has ≥10 recurrences per year
- Previous failure on lower-dose valacyclovir
Choose acyclovir 400 mg twice daily IF:
- Cost is a major concern (generic acyclovir is least expensive)
- Patient has extensive prior experience with acyclovir
Key Clinical Points
- All regimens reduce recurrence frequency by ≥75% in patients with frequent recurrences (≥6 per year) 1, 7
- Suppressive therapy does NOT eliminate asymptomatic viral shedding or completely prevent transmission 1
- Reassess after 1 year of continuous therapy to evaluate recurrence patterns, as frequency naturally decreases over time in many patients 1
- No clinically significant acyclovir resistance has emerged in immunocompetent patients on suppressive therapy 1
Common Pitfall
Do not use valacyclovir 250 mg twice daily for patients with very frequent recurrences - this lower dose is inadequate for optimal suppression in this population 1.